002898 Sailong Pharmaceutical Group
- 10.72
- +0.66+6.56%
Sailong Pharmaceutical Group News
Sailong Pharmaceutical: Announcement on preparation for impairment calculation for the first three quarters of 2024
Sailong Pharmaceutical: Review Opinions of the Third Meeting of the Fourth Board Audit Committee in 2024
Sailong Pharmaceutical: Explanation of the Supervisory Board on the reasonableness of the company\'s impairment preparations
Sailong Pharmaceutical: Explanation of the Board of Directors and Audit Committee on the reasonableness of the company\'s impairment preparations
Cailong Pharmaceutical: Announcement on the Election of the Chairman of the Supervisory Board
Sailong Pharmaceutical: Legal Opinion on the 2024 Fourth Extraordinary General Meeting of Shareholders of Sailong Pharmaceutical Group Co., Ltd.
Cailong Pharmaceutical: Announcement of Resolutions of the 2024 Fourth Extraordinary General Meeting of Shareholders
Sailong Pharmaceutical: Announcement on completing the by-election of non-employee representative supervisors of the 4th board of supervisors
Sailong Pharmaceutical: Announcement on Subsidiaries Obtaining Approval Notice for Chemical Raw Material Marketing Applications
Sailong Pharmaceutical: Announcement on the progress of the “Headquarters Project Cooperation Agreement” and its supplementary agreement
Sailong Pharmaceutical: Announcement on Subsidiaries Obtaining Approval Notice for Chemical Raw Material Marketing Applications
Sailong Pharmaceutical: Announcement on the Resignation of the Company\'s Supervisor and the By-election of Non-Employee Representative Supervisors
Sailong Pharmaceutical: Notice on Convening the Fourth Extraordinary General Meeting of Shareholders in 2024
Sailong Pharmaceutical: Legal Opinion of Beijing Kangda Law Firm on the 2024 Third Extraordinary General Meeting of Shareholders of Sailong Pharmaceutical Group Co., Ltd.
Sailong Pharmaceutical: Announcement of Resolutions of the 2024 Third Extraordinary General Meeting of Shareholders
Sailong Pharmaceutical: Announcement on Subsidiaries Obtaining Approval Notice for Chemical Raw Material Marketing Applications
Sailong Pharmaceutical: Announcement on Subsidiaries Obtaining Approval Notice for Chemical Raw Material Marketing Applications
Sailong Pharmaceutical: Explanation of the Board of Directors and Audit Committee on the reasonableness of the company\'s impairment preparations
Sailong Pharmaceutical: Semi-annual Non-Operating Capital Occupancy and Other Related Capital Transactions Summary
Cailong Pharmaceuticals: 2024 Semi-Annual Financial Report
Analysis
Price Target
No Data
No Data